KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-Current Assets (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Non-Current Assets for 17 consecutive years, with $60.7 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 5.12% to $60.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $237.9 billion through Dec 2025, up 14.2% year-over-year, with the annual reading at $60.7 billion for FY2025, 5.12% up from the prior year.
  • Non-Current Assets hit $60.7 billion in Q4 2025 for Abbott Laboratories, up from $59.3 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $60.7 billion in Q4 2025 to a low of -$22.3 billion in Q4 2022.
  • Historically, Non-Current Assets has averaged $46.8 billion across 5 years, with a median of $50.4 billion in 2021.
  • Biggest five-year swings in Non-Current Assets: plummeted 270.54% in 2022 and later skyrocketed 326.24% in 2023.
  • Year by year, Non-Current Assets stood at $13.1 billion in 2021, then tumbled by 270.54% to -$22.3 billion in 2022, then surged by 326.24% to $50.5 billion in 2023, then grew by 14.27% to $57.8 billion in 2024, then rose by 5.12% to $60.7 billion in 2025.
  • Business Quant data shows Non-Current Assets for ABT at $60.7 billion in Q4 2025, $59.3 billion in Q3 2025, and $59.5 billion in Q2 2025.